DESOXYAZAPHOSPHOLIPID DERIVATIVES HAVING INHIBITING ACTIVITY ON PHOSPHOLIPASE A2

Abstract: The invention relates to a series of novel desoxyazaphospholipid derivatives which exhibit inhibiting activity on phospholipase A2, the pharmaceutically acceptable salts thereof, a process for the preparation thereof, pharmaceutical compositions containing said compounds, and the use thereof in therapy.

Description: DESOXYAZAPHOSPHOLIPID DERIVATIVES HAVING INHIBITING ACTIVITY ON PHOSPHOLIPASE A2. The present invention relates to a series of novel desoxyazaphospholipid derivatives which exhibit inhibi¬ ting activity on phospholipase A_, the pharmaceutically acceptable salts thereof, a process for the preparation 5 thereof, pharmaceutical compositions containing said compounds, and the use thereof in therapy. TECHNOLOGICAL BACKGROUND It is well established that most eicosanoides, prostaglandins and related compounds derive from a 10 fatty acid having 20 carbons and 4 insaturations, na¬ mely arachidonic acid (AA) , which is mainly found when esterifying the hydroxy group at the 2-position of gly- cerol of the phospholipids contained in the cell mem¬ branes. AA is released from the phospholipid which con- 15 tains it by the action of a lipase, i.e. phospholipase A_ (PLA_) ("CRC Handbook of Eicosanoids and Related Li- pids", vol. II, Ed. A.L.Willis, CRS Press, Inc. Florida (1989)). Once AA is released, it is metabolized in mammals 20 mainly by two different pathways or enzyme systems. Through cyclo-oxygenase it produces prostaglandins and thromboxanes, the most significant being PGE~ and TxA_, which participate directly in inflammation (Higgs et al. Annals of Clinical Research, 16, 287-299 (1984)). 25 Through lipoxygenases it produces leukotrienes, the most important being LTB. , LTC, and LTD., which also participate in inflammatory reactions, show chemotactic activities, stimulate the secretion of lysosomial enzy¬ mes and act as important factors in immediate hypersen- sitivity reactions (Bailey and Casey, Ann. Rep. Med. Chem. , 17, 203-217 (1982)). By the action of PLA-, besides the release of fatty acids, the corresponding lysophospholipids are obtained, which can be reesterified or, if they have phosphocholine at the 3-position, an ether bond at the 1-position and are in a cellular system with acetyl- transferase activity, can be acetylated at the 2-posi- tion, becoming PAF (platelet activating factor). PAF is also a proinflammatory agent, which is supposed to play an important role in various pathological processes, such as asthma, anaphylaxis, inflammation and ischemia (Braquet et al., Pharmacol. Rev. , 39 (2), 97 (1987)). Besides its relation with inflammatory processes, PLA 2 can have other direct consequences on some patho¬ logical processes of thrombotic degenerative and cance¬ rous type. From what said above it is evident that PLA 2 plays an important role in the control of the production of the mediators involved in the above mentioned patholo¬ gies. As a consequence, PLA 2 -inhibiting compounds are a new rational approach to the prevention, elimination or improvement of differemt allergic, anaphylactic, asthmatic, inflammatory and thrombotic conditions. Even though various compounds have been described as "in vitro" inhibitors of PLA 2 (Wilkerson, Drugs of the Future, 15, 141 (1990)), at present there are no specific inhibitors of PLA 2 of clinical use. Some compounds described in literature as inhibitors of PLA 2 are related structurally with the compounds of the present invention, but they are not included in the general formula (I) (De Haas G. H. et al., Biochi . Biophys. Acta, 1046,. 249 (1990)). Also, references were found on compounds similar to the ones of the present invention, not included in formula (I), with a sulfonamido group at the 2-position, which exert a very weak inhibiting action on PLA 2 (Deveer A.M.Th.J et al., Biochim. Biophys. Acta, 1125, 73 (1992). Surprisingly, the derivatives with a sulfonamido group at the 2-position included in formula (I), particularly when they have as a polar head a substituent with a terminal phenylmethyl group, turned out to be very strong inhibitors of PLA 2 . So far the only drugs in which a PLA 2 inhibition mechanism was supposed, even if in an indirect way, are corticosteroids. However, these compounds exhibit a number of negative systemic side-effects limiting their use, particularly in chronic pathologies. Selective inhibitors of PLA 2 , such as the compounds of the pre¬ sent invention, have the advantage of exhibiting the same effectiveness as corticosteroids, but without the side effects thereof. DISCLOSURE The present invention relates to a series of novel desoxyazaphospholipid derivatives, the salts thereof, a process for the preparation thereof and pharmaceutical compositions containing them. The compounds of the invetion have general formula (I), I wherein R is hydrogen or phenyl; n is an integer from 2 to 18 included; A is a -CO- or -S0 2 ~ group; R 2 is a C,-C 20 straight or branched alkyl group or a phenylalkyl of less than 20 carbon atoms; B is an oxygen atom or a methylene group; 3 R is hydrogen, a ^-Cg straight or branched alkyl, a phenylalkyl group of less than 12 carbon atoms, a 4 -(CH 2 ) OR group, wherein m is a integer from 2 to 6 4 and R is hydrogen, a C,-C. straight or branched alkyl group, or a phenylalkyl group of less than 10 carbon atoms, or a -(CH 2 ) CH(R )NHR group, wherein p is a in- teger from 1 to 4, R 5 is hydrogen or a carboxyl group and R is hydrogen, a C,-C. straight or branched alkyl group, a phenylalkyl group of less than 10 carbon atoms; with the proviso that the -B-R group cannot be -OCH 2 CH 2 OH when A is -CO- and R is H, nor when A is -S0 2 -, R is hydrogen and n is lower than 5. The compounds of general formula (I) can be prepa¬ red in form of salts represented by formula (la), la wherein M + is an alkali metal cation (such as Na , K ) , or the half amount of an alkaline-earth metal cation (such as 1/2 Ca 2+ , 1/2 Mg 2+ ). 3 When R contains an amino group, compounds of for¬ mula (I) can also be obtained in form of salts, as re¬ presented by formula (lb) (CH 2 ) n R' R2—A—NH—CH O X " C IH 2 —O—PII—B—(CH 2 ) p —CH— + NH 2 -R-«. OH R 5 lb wherein X~ is a pharmaceutically acceptable anion, such as chloride, bromide, iodide, acetate, trifluoroacetate or lactate and the other symbols are as defined above. The compounds of general formula (I) contain one or more asymmetric carbons. The present invention in¬ cludes all the possible stereoisomers as well as the mixtures thereof. 2 In the compounds of general formula (I), R can be for example methyl, ethyl, butyl, sec-butyl, isobutyl, pentyl, hexyl, decyl, undecyl, dodecyl, tetradecyl, pentadecyl , hexadecyl, heptadecyl, octadecyl, nona- decyl, icosyl, phenylmethyl, 3-phenylpropyl, 6-phenylhexyl, 8-phenyloctyl, 9-phenylnonyl, 11-phenylundecyl or 12-phenyldodecyl; when R is an alkyl or phenylalkyl group, this can be for example methyl, ethyl, propyl, butyl, sec-butyl, isobutyl, pentyl, hexyl, phenylmethyl, 2-phenylethyl, 3-phenylpropyl, 4-phenylbutyl or 5-phenylpentyl; when 3 4 4 R is a -(CH 2 ) OR group and R is an alkyl or pheny¬ lalkyl group, this can be for example methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, phenylmethyl, 3 2-phenylethyl or 3-phenylpropyl; when R is a - (CH ) CH(R 5 )NHR 6 group, and in its turn R is an alkyl __. p or phenylalkyl group, this can be for example methyl, ethyl, propyl, butyl, sec-butyl, isobutyl, phenyl¬ methyl, 2-phenylethyl or 3-phenylpropyl. Preferred compounds of the invention are those in which: - R , A, B and n have the above mentioned meanings; 2 - R is an alkyl group, preferably hexyl, octyl, decyl, undecyl, dodecyl, pentadecyl or hexadecyl; or a pheny¬ lalkyl group, preferably 3-phenylpropyl, 4-phenylbutyl, 6-phenylhexyl or 8-phenyloctyl; 3 - R is hydrogen, methyl, ethyl, propyl, butyl, phenyl- methyl, 2-phenylethyl, 3-phenylpropyl, 2-hydroxyethyl, 2-benzyloxyethyl, 2-aminoethyl, or 2-amino-2-car- boxyethyl. Particularly preferred compounds of the invention are the following ones: (R)-2-Decanesulfonylaminohexanol-l-phospho-2-benzy- loxyethanol. (S)-2-Decanesulfonylaminohexanol-l-phospho-2-benzy- loxyethanol. 2-Decanesulfonylaminooctanol-l-phospho-2-benzyloxyetha- nol. (R)-2-Decanesulfonylaminooctanol-l-phospho-2-benzy- loxyethanol. (S)-2-Decanesulfonylaminooctanol-l-phospho-2-benzy- loxyethanol. 2-Decanesulfonylaminodecanol-l-phospho-2-benzyloxyetha- nol. 2-Decanesulfonylaminotetradecanol-l-phospho-2-benzy- loxy-ethanol. 2-Decanesulfonylaminooctadecanol-l-phospho-2-benzy- loxyethanol. 2-Decanesulfonylaminooctanol-1-phosphoglycol. 2-Dodecanoylaminooctanol-l-phospho-2-benzyloxyethanol. 2-(3-Phenylpropanesulfonylamino)octanol-l-phospho-2- benzyloxyethanol. 2-Decanesulfonylamino-4-phenylbutanol-l-phospho-2-ben- zyloxyethanol. 2-Decanesulfonylamino-8-phenyloctanol-l-phospho-2-ben- zyloxyethanol. 2-Dodecanoylamino-8-phenyloctanol-l-phospho-2-benzy- loxyethanol. 2-Decanesulfonylamino-14-phenyltetradecanol-l-phospho- 2-benzyloxyethanol. 2-Hexanesulfonylaminooctanol-l-phospho-2-benzyloxyetha- nol. 2-Hexanoylaminooctanol-l-phospho-2-benzyloxyethanol. 2-Dodecanesulfonylaminooctanol-l-phospho-2-benzy- loxyethanol. 2-Hexadecanesulfonylaminooctanol-l-phospho-2-benzy- loxyethanol. 2-(6-Phenylhexanesulfonylamino)octanol-l-phospho-2-ben- zyloxyethanol. 2-(6-Phenylhexanoylamino)octanol-l-phospho-2-benzy- loxyethanol. 2-Dodecanoylaminooctanol-l-phosphoserine. 2-Decanesulfonylaminooctanol-l-phosphoserine. 2-Decanesulfonylaminooctanol-1-phosphoethanolamine (trifluoroacetic acid salt). 2-Dodecanoylaminooctanol-l-phosphoethanolamine (acetic acid salt) . 2-Decanesulfonylaminooctanol-l-phosphoethanol. 2-Dodecanoylaminooctanol-l-phosphoethanol. 2-Dodecanoylaminooctanol-l-phosphate. 2-Decanesulfonaminooctyl butylphosphonate. 2-Decanesulfonaminooctyl (4-phenylbutyl)phosphonate. 2-Dodecanoylaminooctyl butylphosphonate. 2-Dodecanoylaminooctyl (3-hydroxypropyl)phosphonate. 2-Dodecanoylaminooctyl (3-benzyloxypropyl)phosphonate. According to the present invention, the compounds of general formula (I) are obtained starting from a compound of formula (II) of suitable stereochemistry at the 2-carbon, II wherein R 1, n, A and R2 have the above mentioned mea¬ nings, which is reacted with different reactive, depen¬ ding on the meanings of B in formula (I), a) When in (I) B is oxygen, compound (II) is reacted with a reactive PX 3 , wherein X is a halogen, preferably chlorine, in the presence of a proton-binding base, such as triethylamine, and a mildly nucleophilic base, such as imidazole, in suitable organic solvents, such as acetonitrile, toluene or tetrahydrofuran, at a tem¬ perature from 0° to 40°C, for a time from 3 to 18 hours, to obtain a compound of formula (III), I I I subsequently this intermediate is reacted with a com¬ pound (IV) , HO-R 7 (IV) wherein R 7 can be equivalent to the group R3 i.n formula (I) except for hydrogen; moreover when in (I) R is a -(CH„) OH group, the hydroxy group should suitably be ■i m protected, for example in form of the benzyl or 3 triphenylmethyl ether, when in (I) R is a -( CH 2^ D+ ι NH 2 group, the amino group should be protected with a sui¬ table protecting group, such as the benzyloxycarbonyl 3 or tert-butoxycarbonyl groups, and when in (I) R is a -(CH 2 ) (COOH)NH 2 group, the carboxy group should be suitably protected, for example in form of the benzyl or tert-butyl esters, analogously the amino group should be protected as mentioned above, in an organic solvent, preferably pyridine at a temperature from 0° to 25 β C for a time from 1 to 6 hours, thereby obtaining an intermediate of formula (V) , V which is oxidized, preferably with iodine, in a suita¬ ble solvent, such as humid pyridine, at a temperature from 0° to 25°C for a time from 1 to 5 hours, to give an intermediate (VI), VI wherein R 1, n, A, R2 and R7 are the groups described above. This compound (V ) coincides to (I), or it is converted into (I) by removing any protecting groups 7 present in R , according to methods conventional in 7 chemistry; when in R benzyl protecting groups are pre¬ sent, in form of the benzyl ether for the protection of hydroxy groups, benzyl ether for the protection of car- boxy groups or benzyl carbamate for the protection of amino groups, these can be removed by catalytic hydro- genation with Pd-C or with Pd(0H) 2 , in solvents such as methanol, water or acetic acid, under hydrogen pressu¬ res from atmosphere pressure to 50 psi, at a tempera¬ ture from 20° to 50 β C for a time from 3 to 20 hours; 7 or, when in R protecting groups are present such as triphenylmethyl to protect hydroxy groups, tert-butyl to protect carboxy groups or tert-butyloxycarbonyl to protect amino groups, these can be removed in acidic medium, for example with hydrobromic, hydrochloric or trifluoroacetic acids, in a suitable solvent such as dioxane, tetrahydrofuran or chloroform, at a tempera¬ ture from 0 β to 40°C for a time from 15 minutes to 6 hours. 3 When in (I) R is hydrogen, this compound can be obtained by direct oxidation of an intermediate (III) analogously to what indicated for the oxidation of a compound (V). b) When in (I) B is a methylene group, compound (II) is reacted with a reactive (VII), VII wherein Y is halogen, preferably chlorine, Z is halo¬ gen, preferably chlorine, or a methoxide group, in the presence of an amine such as triethylamine or N,N-di- methylaminopyridine, in a suitable organic solvent, such as chloroform or methylene chloride at a tempera¬ ture from 0 β to 40 β C for a time from 3 to 24 hours, to obtain an intermediate of formula (VIII), VIII wherein R 1 , n, A, R2 , Z and R 7 have the above mentioned meanings. After that, by acid hydrolysis in an aqueous medium, preferably using diluted hydrochloric acid, when Z is halogen, or by treatment with a suitable nu- cleophilic agent such as trimethylamine or sodium io¬ dide, when Z is a methoxy group, compound (IX) is ob- tained, IX wherein R 1 , n, A, R 2 and R 7 have the above mentioned meanings. This compound (IX) coincides to (I), or it can be converted into (I) by removing any protecting 7 groups present in R , according to the methods mentio¬ ned above. Finally, if a specific salt of (I) is desired, the compound is treated with the acid, the base or the sui¬ table ion exchanger, according to conventional methods. A starting compound (II) can be obtained, for example, following the synthetic sequence shown in Scheme 1. Scheme 1 x XI XII II In the above sequence, which is used when the starting products of formula (X) are commercially avai- lable, a compound of formula (XI) can be obtained (step a) , for example, reacting the compound (X) with thionyl or oxalyl chloride in methanol, at a temperature from - 30° to 20 β C, for a time from 12 to 48 hours. A compound of formula (XII) can be obtained (step b) reacting the compound (XI) with a compound R 2-A-Y, wherein R 2 and A have the above mentioned meanings and Y can be iodide, chloride or bromide, in the presence of a base such as triethylamine, pyridine or N,N-dimethylaminopyridine, in a suitable solvent such as chloroform or methylene chloride, at a temperature from 0 β to 40 β C, for a time from 1 to 24 hours. A compound of formula (II) can be obtained (step c_) reacting a compound (XII) with a suitable metal hy¬ dride such as sodium borohydride, in an organic solvent such as methanol, ethanol or tetrahydrofuran in the presence of a catalytic amount of water, at a tempera¬ ture from 20° to solvent reflux for a time from 3 to 24 hours. Alternatively, when the starting compound (X) is not commercially available, a compound (II) can be ob- tained, for example, by the synthetic sequence shown in Scheme 2. Scheme 2 XI I I XV XVI XVI I XVI I I <CH 2 ) n — R 1 (CH 2 ) n — R 1 ^ .- CH-OTS ^— H 2 N— CH I I CH 2 -OTr CH 2 -OTr R2 _ A _ NH XXI II In this synthetic sequence the starting compounds are compound (XIII), which is commercially available as both the R and S enantiomer, and a compound (XIV), whe¬ rein R has the above mentioned meanings and q is an integer from 0 to 16, said compound can be obtained starting from the corresponding bromide, BrCH 2 (CH ? ) R , 1 " which if R is hydrogen is commercially available and if R is phenyl can be prepared by the procedure di- sclosed in ES-2034884. Said bromide is treated with triphenylphosphine in a suitable solvent such as aceto- nitrile or tetrahydrofuran at a temperature from 25 β C to solvent reflux, for a time from 12 to 96 hours. In step d, a compound (XIV) is subjected first to the action of a strong base such as n-butyl lithium or sodium amide, thereafter it is reacted with a compound (XIII) in a suitable solvent such as benzene, dimethyl- formamide or tetrahydrofuran, at a temperature from 0° to 25°C for a time from 3 to 24 hours, thus obtaining a compound (XV), wherein q and R have the above mentio¬ ned meanings. A compound (XVI) can be obtained starting from a compound of formula (XV) (step e) by acid hydrolysis with hydrochloric or sulfuric acids, in a suitable sol¬ vent such as tetrahydrofuran or dioxane, at a tempera¬ ture from 25 β C to solvent reflux, for a time from 1 to 4 hours. A compound (XVII) can be prepared for example starting from a compound (XVI), by catalytic hydrogena- tion with a suitable catalyst, such as Pd-C or Pd(OH) 2 - C in a solvent such as ethanol or methanol, under hy¬ drogen pressures from atmospheric pressure to 25 psi, at a temperature from 25° to 50°C, for a time from 3 to 24 hours (step f) . A compound (XVIII) can be obtained for example by step 2» starting from a compound (XVII), which is reac¬ ted with trityl chloride in a solvent acting as the base, such as pyridine or triethylamine, at a tempera- ture from 25° to 100°C, for a time from 8 to 48 hours. A compound (XIX) can be obtained for example by treatment of a compound (XVIII) (step h) with p-tolue- nesulfonic acid chloride in the presence of a base such as pyridine or triethylamine which can in their turn act as the solvents, the presence of other solvents such as chloroform or methylene chloride being optio¬ nal, at a temperature from 0° to 40 β C for a time from 3 to 18 hours. A compound of formula (XX) can be prepared for example starting from a compound (XIX) (step i) by sub- stituting the tosylated group with an azido group, using sodium azide as the reactive, in a suitable orga¬ nic solvent such as dimethylformamide or tetrahydrofu¬ ran at a temperature from 20 β C to solvent reflux for a time from 6 to 24 hours; and subsequent catalytic hy- drogenation of the intermediate azide with a suitable catalyst such as Pd-C or in a solvent such as ethanol, methanol or ethyl acetate, under hydrogen pressures from atmospheric pressure to 25 psi, at a temperature from 0 β to 50°C, for a time from 6 to 24 hours. A compound (XXI) can be prepared for example star¬ ting from a compound (XX) (step ~ \ ) by treatment with a reactive R -A-Y, as described above for the preparation of a compound (XII). Finally, a compound (II) can be obtained by de- tritylation of a compound (XXI) (step k) which can be carried out in acidic medium, using acids such as £-to- luenesulfonic, hydrochloric or acetic acids, in a sui¬ table solvent such as dioxane, ethanol or THF, at a temperature from 25° to 80°C, for a time from 2 to 12 hours. The compounds of the present invention show a marked activity as inhibitors of PLA 2 activity, thus exerting antiinflammatory and antiallergic actions which make them valuable in the treatment of those di¬ seases in which this enzyme is involved. Therefore, said compounds can be used in human therapy, for the prevention and treatment of allergic rhinitis, bron¬ chial asthma, hypersensitivity reactions such as aller¬ gic conjunctivitis, various inflammatory conditions, such as those present in rheumatic arthritis, osteoar- thritis, tendinitis, bursitis, psoriasis and . other re¬ lated inflammations. For the therapeutical use, the compounds of the present invention, are formulated in suitable pharma¬ ceutical formulations, according to conventional te- chniques and excipients, such as those described in Re¬ mington's Pharmaceutical Science Handbook, Mack Pub. Co., N.Y. , USA. Examples of said formulations include capsules, tablets, syrups and the like, containing 1 to 1000 mg per unitary dose. EXAMPLES The following examples illustrate the preparation and the pharmacological activity of the compounds of the present invention. EXAMPLE 1 Methyl 2-aminooctanoate (XI, R 1 -H, n-6). A solution of thionyl chloride (3.24 ml, 44.6 mmol) in methanol (20 ml), at -10°C is added with 2 g (12.5 mmol) of 2-aminooctanoic acid. The mixture is stirred at room temperature for 24 h, then it is evapo- rated to dryness, to obtain 2.6 g of the title compound as a white solid melting at 94-95°C (93% yield). N.M.R. X H (300 MHz, CDC1 ) ζ ppm: 0.82 (t, 3H) ; 1.30 (m, 8H); 1.98 (m, 2H); 3.78 (s, 3H); 4.05 (m, 1H). EXAMPLE 2 Methyl (R)-2-aminohexanoate (XI, R 1 -H, n-4) . Following the process described in Example 1, starting from (R)-2-aminohexanoic acid (D-norleucine) the title compound is prepared as a white solid melting at 140-141 β C (98 % yield). [ø<] D 20 =-20.3 β (c-1.04, chloroform) N.M.R. 1 H (300 MHz, CDC1 3 ) £ ppm: 0.89 (t, 3H) ; 1.40 (m, 4H); 2.00 (m, 2H); 3.79 (s, 3H); 4.10 (m, 1H). EXAMPLE 3 Methyl (S)-2-aminohexanoate (XI, R -H, n-4). Following the process described in Example 1, starting from (S)-2-aminohexanoic acid (L-norleucine) , the title compound is prepared as a white solid melting at 140-141°C (95 % yield). (c-1.18, chloroform) N.M.R. 1 H (300 MHz, CDC1 3 )S ppm:0.89 (t, 3H) ; 1.40 (m, 4H); 2.00 (m, 2H) ; 3.79 (s, 3H) ; 4.10 (m, 1H) . EXAMPLE 4 Methyl 2-amino-4-phenylbutanoate (XI, R -C 8 H c , n=2). Following the process described in Example 1, starting from 2-amino-4-phenylbutanoic acid (D,L-ho- mophenylalanine) , the title compound is prepared as a white solid melting at 110-112°C (95 % yield). N.M.R. 1 H (300 MHz, CDC1 3 ) € ppm: 2.25 (m, 2H) ; 2.78 (m, 2H); 3.80 (s, 3H) ; 4.80 (m, 1H) ; 7.20 (m, 5H). EXAMPLE 5 Methyl 2-decanesulfonylaminooctanoate (XII, R -H, n-6, A-S0 2 , R 2 =(CH 2 ) 9 CH 3 ). A solution of methyl 2-aminooctanoate (9.3 g, 53.9 mmol) in dry chloroform (200 ml) at 0 β C is added with triethylamine (23 ml, 162 mmol) and decanesulfonyl chloride (18.1 g, 75.4 mmol). The mixture is stirred at room temperature for 18 h. After that the mixture is diluted with chloroform (200 ml), washed with water, dried and the solvent is removed, to obtain a crude compound which is purified by flash chromatography on a silica gel column. Eluting with 5:1 hexane:ethyl ace- tate, 15 g of the title compound are obtained (71% yield) . N.M.R. 1 H (300 MHz, CDCl- j ) S ppm: 0.89 (t, 6H) ; 1.27 (m, 22H); 1.75 (m, 4H) ; 2.95 (t, 2H) ; 3.78 (s, 3H); 4.08 (m, 1H). EXAMPLE 6 Methyl (R)-2-decanesulfonylaminohexanoate (XII, R -H, n-4, A-S0 2 , R 2 -(CH 2 ) g CH 3 ). Following the process described in Example 5, starting from methyl (R)-2-aminohexanoate, the title compound is prepared as a white solid melting at 38- 39°C (77 % yield). tø] D 20 —2.4° (c=1.07, chloroform) N.M.R. 1 H (300 MHz, CDCl- j ) & ppm: 0.89 (t, 6H) ; 1.30 (m, 18H); 1.75 (m, 4H) ; 2.95 (t, 2H) ; 3.74 (s, 3H) ; 4.05 (m, 1H) . EXAMPLE 7 Methyl (S)-2-decanesulfonylaminohexanoate (XII, R -H, n-4, A-S0 2 , R 2 -(CH 2 ) 9 CH 3 ). Following the process described in Example 5, starting from methyl (S)-2-aminohexanoate, the title compound is prepared as a white solid melting at 38- 39°C (90 % yield). [oU D 20 =+1.8 p (c=1.02, chloroform) N.M.R. 1 H (300 MHz, CDC1 3 ) 5 ppm: 0.89 (t, 6H); 1.30 (m, 18H); 1.75 (m, 4H) ; 2.95 (t, 2H) ; 3.74 (s, 3H) ; 4.05 (m, 1H). EXAMPLE 8 Methyl 2-dodecanoylaminooctanoate (XII, R -H, n-6, A-CO, R 2 -(CH 2 ) 10 CH 3 ). Following the process described in Example 5, starting from methyl 2-aminooctanoate and dodecanoyl chloride, the title compound is prepared as a colour¬ less oil (74% yield). N.M.R. *H (300 MHz, CDC1 3 ) S ppm: 0.88 (t, 6H) ; 1.26 (m, 24H) ; 1.63 (m, 4H) ; 2.22 (t, 2H); 3.75 (s, 3H); 4.63 (m, 1H) . EXAMPLE 9 Methyl 2-(3-phenylpropanesulfonylamino)octanoate (XII, R^H, n-6, A-S0 2 , R 2 -(CH 2 ) 3 C 6 H 5 ). Following the process described in Example 5, starting from methyl 2-aminooctanoate and 3-phenylpro- panesulfonyl chloride, the title compound is prepared as a yellowish oil (91% yield). N.M.R. 1 H (300 MHz, CDC1 3 ) $ p pm: 0.85 (t, 3H) ; 1.24 (m, 8H); 1.68 (m, 2H) ; 2.10 (m, 2H) ; 2.71 (t, 2H); 2.95 (t, 2H); 3.70 (s, 3H) ; 4.00 (m, 1H) ; 7.20 (m, 5H) . EXAMPLE 10 Methyl 2-decanes lfonylamino-4-phenylbutanoate (XII, R 1 -CgH 5 , n=2, A-S0 2 , R 2 -(CH 2 ) 9 CH 3 ). Following the process described in Example 5, starting from methyl 2-amino-4-phenylbutanoate, the ti¬ tle compound is prepared as a semisolid oil (75 % yield) . N.M.R. 1 H (300 MHz, CDCl- j ) g ppm: 0.88 (t, 3H) ; 1.30 (m, 14H); 1.82 (m, 2H) ; 2.09 (m, 2H) ; 2.75 (m, 2H) ; 3.00 (m, 2H); 3.70 (s, 3H) ; 4.12 (m,.lH); 7.20 (m, 5H) . EXAMPLE 11 2-Decanesulfonylaminooctanol (II, R -H, n-6, A-S0 2 . R 2 -(CH 2 ) g CH 3 ). A solution of methyl 2-decanesulfonylaminooctano- ate (7.5 g, 19.8 mmol) in THF (120 ml) is added with NaBH^ (3.0 g, 79.4 mmol) and some drops of water. The mixture is refluxed for 18 h, then it is cooled to room temperature and the hydride excess is destroyed by ad¬ dition of a 1M HC1 solution (20 ml). Volatiles are eli¬ minated under reduced pressure and the residue is dis- solved in 500 ml of water-ethyl ether (1:2). The two phases are separated and the aqueous one is extracted with ethyl ether. The combined ethereal phases are dried and the solvent is removed, to obtain a crude compound which is purified by flash chromatography on a silica gel column. Eluting with 1:1 hexane:ethyl ace¬ tate, 6.3 g of the title compound are obtained as a white solid melting at 71-72 β C (90 % yield). N.M.R. 1 H (300 MHz, CDC1 3 ) S ppm: 0.83 (t, 6H) ; 1.33 (m, 24H); 1.76 (m, 2H) ; 3.00 (t, 2H) ; 3.34 (s, 1H) ; 3.45-3.70 ( , 2H) . EXAMPLE 12 (R)-2-Decanesulfonylaminohexanol (II, R -H, n-4, A-S0 2 , R 2 -(CH 2 ) 9 CH 3 ). Following the process described in Example 11, starting from methyl (R)-2-dodecanesulfonylaminohexa- noate, the title compound is prepared as a white solid melting at 76-77°C (83 % yield). [øfl D 20 -+11.4° (c-0.96, chloroform) N.M.R. 1 H (300 MHz, CDC1 3 ) £ ppm: 0.88 (t, 6H) ; 1.34 ( , 20H); 1.80 (m, 2H); 3.04 (m, 2H); 3.39 (m, 1H); 3.50-3.75 (m, 2H) . EXAMPLE 13 (S)-2-Decanesulfonylaminohexanol (II, R -H, n-4, A-S0 2 , R 2 -(CH 2 ) 9 CH 3 ). Following the process described in Example 11, starting from methyl (S)-2-dodecanesulfonylami- nohexanoate, the title compound is prepared as a white solid melting at 76-77°C (77 % yield). W] D 20 —11.5° (c-0.99, chloroform) N.M.R. 1 H (300 MHz, CDC1 3 ) 8 ppm: 0.88 (t, 6H) ; 1.34 (m, 20H); 1.80 (m, 2H) ; 3.04 (m, 2H) ; 3.39 (m, 1H) ; 3.50-3.75 (m, 2H) . EXAMPLE 14 2-Dodecanoylaminooctanol (II, R -H, n-6, A=CO, R 2 -(CH 2 ) 1Q CH 3 ). Following the process described in Example 11, starting from methyl 2-decanoylaminooctanoate, the ti¬ tle compound is prepared as a white solid melting at (86 % yield). N.M.R. 1 H (300 MHz, CDC1 3 ) S ppm: 0.88 (t, 3H) ; 1.26 (m, 24H); 1.55 (m, 4H); 2.20 (t, 2H); 3.62 (m, 2H) ; 3.94 (m, 1H). EXAMPLE 15 2-(3-Phenylpropanesulfonylamino)octanol (II, R -H, n-6, A-S0 2 , R 2 -(CH 2 ) 3 c 6 H 5 ). Following the process described in Example 11, starting from methyl 2-(3-phenylpropanesulfonylami- no)octanoate, the title compound is prepared as a yellowish solid melting at 60-61°C (90% yield). N.M.R. 1 H (300 MHz, CDC1 3 ) $ ppm: 0.85 (t, 3H) ; 1.25 (m, 8H); 1.45 (m, 2H) ; 2.12 (m, 2H); 2.70 (t, 2H) ; 3.00 (m, 2H); 3.30 (m, 1H) ; 3.40-3.68 (m, 2H) ; 7.20 (m, 5H) . EXAMPLE 16 2-Decanesulfonylamino-4-phenylbutanol (II, R -CgH c , n-2, A-S0 2 , R 2 -(CH 2 ) 9 CH 3 ). Following the process described in Example 11, starting from methyl 2-decanesulfonylamino-4-ρhenylbu- tanoate, the title compound is prepared as a white so¬ lid melting at 71-72°C (90% yield). N.M.R. 1 H (300 MHz, CDC1 3 ) ξ p pm: 0.89 (t, 3H) ; 1.28 (m, 14H); 1.82 (m, 4H); 2.72 (m, 2H) ; 3.00 (m, 2H) ; 3.45 (m, 1H) ; 3.55-3.70 (m, 2H) ; 7.20 (m, 5H) . EXAMPLE 17 (S)-2,2-Dimethyl-4-(1-hexenyl)-1,3-dioxolane (XV, R 1 -H, q-4). Pentyltriphenylphosphonium bromide A solution of pentyl bromide (15.0 g, 99.3 mmol) in acetonitrile (250 ml), is added with 28.6 g (109.3 mmol) of triphenylphosphine. After refluxing for 4 days, the mixture is evaporated to dryness and the re¬ sidue is treated with ethyl ether, to obtain 30.8 g of the title compound as a white solid melting at 162- 165°C (75 % yield). (S)-2,2-Dimethy1-4-(1-hexenyl)-1,3-dioxolane A solution of pentyltriphenylphosphonium bromide (21.7 g 52.5 mmol) in anhydrous THF (150 ml) at 0 β C and under inert atmosphere, is added with a 1.1M solution of butyl lithium (47.7 ml, 52.5 mmol). The mixture is stirred at 0°C for 1.5 h, after that a solution of (R)- 2,3-0-isopropylideneglyceraldehyde previously distilled (6.2 g, 48.2 mmol) in THF (50 ml) is added. After stir¬ ring at 0 β C for 18 h, the solvent is -evaporated off to obtain a crude compound which is purified by flash chromatography on a silica gel column. Eluting with 9:1 petroleum ether:ethyl ether, 8.5 g of the title com¬ pound are obtained as a colourless oil (96 % yield). [rt] D 20 «+7.8° ( C =1.01, chloroform) N.M.R. X H (300 MHz, CDC1 3 ) £ ppm: 0.89 (t, 3H) ; 1.30 (m, 4H); 1.39 (s, 3H) ; 1.42 (s, 3H) ; 2.12 (m, 2H) ; 3.50 (t, 1H); 4.04 (dd, 1H) ; 4.83 ( , 1H) ; 5.39 (m, 1H) ; 5.62 (m, 1H). EXAMPLE 18 (S)-3-Octen-l,2-diol (XVI, R^H, q-4). A solution of (S)-2,2-dimethyl-4-(1-hexenyl)-1,3- dioxolane (8.5 g, 46.2 mmol) in THF (250 ml) is added with 220 ml of 6N HC1. The mixture is stirred for 2 h at room temperature and neutralized with NaHCO^, the two phases are separated and the aqueous one is extrac¬ ted with ethyl acetate, dried and the solvent is evapo¬ rated off, to obtain 5.2 g of the title compound as a colourless oil (quantitative yield) . [*] D 20 -+17.5 o (c-1.01, chloroform) 1 H N.M.R. (300MHz, CDC1 3 ) 8 ppm: 0.87 (t, 3H) ; 1.31 (m, 4H); 2.07 ( , 2H) ; 3.50 (m, 2H); 4.51 (m, 1H); 5.32 (m, 1H); 5.53 (m, 1H) . EXAMPLE 19 (S)-3-Octan-l,2-diol (XVII, R 1 -H, n-6). A solution of (S)-3-octen-l,2-diol (1.3 g, 9.4 mmol) in methanol (60 ml) is added with 0.135 g of 10 % Pd-C and stirred at room temperature for 18 h, under hydrogen atmosphere. The mixture is filtered and evapo¬ rated to dryness to obtain 1.04 g of the title compound as a colourless oil. (76 % yield). [ert] D 20 - + 2.7 β (c=0.51, chloroform) N.M.R. X H (300 MHz, CDC1 3 ) 8 ppm: 0.85 (t, 3H) ; 1.25 (m, 8H); 1.39 (m, 2H) ; 3.40 (m, 1H) ; 3.61 (m, 2H) . EXAMPLE 20 (S)-l-Triphenylmethoxy-2-octanol (XVIII, R^H, n-6). A solution of 3-octan-l,2-diol (0.85 g, 5.8 mmol) in dry pyridine (30 ml) is added with 3.6 g (11.3 mmol) of trityl chloride. The solution is stirred for 24 h at room temperature. After that, it is poured onto an ice/water mixture, extracted with ethyl ether and wa- shed in turn with 0.1M HC1 to acid pH, 5% NaHC0 3 and water. The mixture is dried and the solvent is evapora¬ ted off, to obtain a crude compound which is purified by flash chromatography on a silica gel column. Eluting with 20:1 petroleum ether:ethyl ether mixtures, 1.9 g of the title compound are obtained as a semisolid oil (84 % yield). toC] D 20 -+7.5 β (c-1.05, chloroform) N.M.R. X H (300 MHz, CDC1 3 ) 5 ppm: 0.89 (t, 3H) ; 1.25 (m, 8H); 1.39 (m, 2H) ; 3.04 (dd, 1H); 3.19 (dd, 1H) ; 3.78 (m, 1H); 7.20-7.50 (m, 15H) . EXAMPLE 21 (S)-2-p-Toluenesulfoxy-l-triphenylmethoxyoctane (XIX, R 1 -H, n-6). A solution of (S)-l-triphenylmethoxy-2-octanol (1.2 g, 3.3 mmol) in chloroform (15 ml) at 0°C is added with 15 ml of pyridine and 1.0 g (5.1 mmol) of p-tolue- nesulfonyl chloride. The mixture is stirred at 0 β C for 5 h. After that it is diluted with water (15 ml) and neutralized with 2M HCl. The two phases are separated and the aqueous one is extracted with chloroform. The combined phases organic are dried and the solvent is removed, to obtain 1.5 g of the title compound as a se¬ misolid oil (84 % yield). (c-0.95, chloroform) N.M.R. 1 H (300 MHz, CDC1 3 ) £ p p m: 0.85 (t, 3H) ; 1.13 (m, 8H); 1.67 (q, 2H) ; 2.42 (s, 3H) ; 3.17 (d, 2H) ; 4.59 (m, 1H); 7.20-7.80 (m, 19H). EXAMPLE 22 (S)-l-Triphenylmethoxymethylheptylamine (XX, R -H, n-6). A solution of (S)-2-p-toluenesulfoxy-l-triphenyl- methoxyoctane (1.4 g, 2.7 mmol) in DMF (50 ml) is added with a solution of sodium azide (0.8 g, 12.3 mmol) in water (20 ml). The mixture is stirred at 70-80 β C for 18 h, after that it is poured into water (30 ml), and ex- tracted with ethyl ether. The ether phase is washed with a sodium chloride saturated solution, dried and the solvent is evaporated off, to obtain a crude com¬ pound which is used directly without purification in the following step. This crude compound is redissolved in ethanol and is added with 0.11 g of 10% Pd-C. The mixture is stir¬ red at room temperature for 1 h, under hydrogen atmo¬ sphere, then it is filtered and evaporated to dryness, to obtain a residue which is purified by flash chroma- tography on a silica gel column. Eluting with 99:1 chloroform:methanol mixtures, 0.7 g of the title com- pound are obtained as a semisolid oil (67 % yield). [ø D 20 --5.9° (c=0.97, chloroform) N.M.R. 1 H (300 MHz, CDC1 3 ) g pp m: 0.87 (t, 3H) ; 1.24 (m, 10H); 2.92 (m, 2H) ; 3.11 (m, 1H); 7.20-7.50 (m, 15H). EXAMPLE 23 (R)-2-Decanesulfonylamino-l-triphenylmethoxyoctane (XXI, R^H, n-6, A-S0 2 , R 2 -(CH 2 ) 9 CH 3 ). Following the process described in Example 5, starting from (R)-l-triphenylmethoxymethylheptylamine, the title compound is prepared as a semisolid oil (89 % yield) . t θ (] D 20 =-0.77 β (c=0.48, chloroform) N.M.R. 1 H (300 MHz, CDC1 3 ) £ ppm: 0.87 (m, 6H) ; 1.25 (m, 22H); 1.63 (m, 4H) ; 2.84 (m, 2H) ; 3.15 (dd, 1H) ; 3.25 (dd, 1H); 3.45 (m, 1H) ; 7.20-7.50 (m, 15H) . EXAMPLE 24 (R)-2-Decanesulfonylaminooctanol (II, R -H, n-6, A-S0 2 , R 2 -(CH 2 ) 9 CH 3 ). A solution of (R)-2-decanesulfonylamino-l- triphenylmethoxyoctane (0.6 g, 1.0 mmol) in dioxane (10 ml) is added with 2.7 ml of 1M HCl. The mixture is stirred at 80 β C for 4h, after that it is neutralized with a NaHC0 3 saturated solution, extracted with ethyl acetate, dried and the solvent is removed, to obtain a crude compound which is purified by flash chromato¬ graphy on silica gel column. Eluting with 7:3 hexane:ethyl acetate, 0.3 g the title compound are ob¬ tained as a white solid melting at 76-78°C (86 % yield). tθ D 20 -+6 .0 β ( c-0 . 96 , chloroform) N.M.R. 1 H (300 MHz, CDC1 3 ) S ppm: 0.83 (t, 6H) ; 1.33 ( , 24H); 1.76 (m, 2H) ; 3.00 (t, 2H); 3.34 (s, 1H); 3.45-3.70 (m, 2H) . EXAMPLE 25 (S)-2-Decanesulfonylaminooctanol (II, R -H, n-6, A-S0 2 , R 2 -(CH 2 ) 9 CH 3 ). Following the process described in Examples 17-24, starting from (S)-2,3-0-isopropylideneglyceraldehyde, the title compound is prepared as a white solid melting at 76-77 β C. [ø(] D 20 =-5.8° (c-0.98, chloroform) N.M.R. 1 H (300 MHz, CDC1 3 ) 8 ppm: 0.83 (t, 6H) ; 1.33 (m, 24H); 1.76 (m, 2H) ; 3.00 (t, 2H); 3.34 (s, 1H) ; 3.45-3.70 (m, 2H) . EXAMPLE 26 2-DecanesuIfonylaminooctanol-l-phospho-2-benzyloxyetha¬ nol (I, R X -H, n-6, A-S0 2 , R 2 -(CH 2 ) 9 CH 3 , B=0, R 3 -CH 2 CH 2 OCH 2 C 6 H 5 ) . A suspension of imidazole (5.6 g, 81.9 mmol), PCI, (2.2 ml, 24.6 mmol), Et 3 N (12 ml, 86.0 mmol) and dry acetonitrile (50 ml) at 0°C under inert atmosphere, is added during 30 min. with 2.0 g (5.7 mmol) of 2-decanesulfonylaminooctanol dissolved in 60 ml of dry toluene. The mixture is stirred for 6h at room tempera- ture, then is added with water, left under stirring for 30 min, evaporated to dryness and redissolved in 150 ml of 4:1 pyridine:Et 3 N, evaporated to dryness, added with water (100 ml), extracted with chloroform and dried. The solvent is removed, to obtain a solid residue which is used in the subsequent step without purification. A mixture of this crude compound (2.7 g, 5.25 mmol), 2-benzyloxyethanol (1.3 g, 9.6 mmol) and 30 ml of dry pyridine is added with 0.76 ml (6.4 mmol) of pi- valoyl chloride. The mixture is stirred for 5 h at room temperature, added with 1.6 ml of water and 1.5 g (5.8 mmol) of iodine. After stirring at room temperature for 45 min, the mixture is added with chloroform (30 ml), washed with a 5 % sodium metabisulfite solution, dried and the solvent is evaporated off, to obtain a crude compound which is purified by flash chromatography on a silica gel column. Eluting with 9:1 chloro- form:methanol, 2.2 g of the title compound are obtained a colourless oil (67 % yield). N.M.R. X H (300 MHz, CDC1 3 ) & ppm: 0.87 (t, 6H) ; 1.25 (m, 24H); 1.78 (m, 2H) ; 2.99 (t, 2H) ; 3.48 (m, 1H); 3.67 (m, 2H) ; 3.90 (m, 1H) ; 4.10 (m, 1H) ; 4.18 (m, 2H) ; 4.55 (s, 2H); 7.30 (m, 5H) . EXAMPLE 27 (R)-2-Decanesulfonylaminooctanol-l-phospho-2-benzy- loxyethanol (I, R 1 -H, n-6, A-S0 2 , R 2 -(CH 2 ) 9 CH 3 , B=0, R 3 -CH 2 CH 2 OCH 2 C 6 H 5 ). Following the process described in Example 26, starting from (R)-2-decanesulfonylaminooctanol, the ti¬ tle compound is prepared as a yellowish oil (54 % yield) . [c(] D 20 -+6.4 β (c-0.43, chloroform). N.M.R. X H (300 MHz, CDC1 3 )£ ppm: 0.87 (t, 6H) ; 1.25 (m, 24H); 1.78 (m, 2H) ; 2.99 (t, 2H); 3.48 (m, 1H); 3.67 (m, 2H) ; 3.90 (m, 1H) ; 4.10 (m, 1H) ; 4.18 (m, 2H) ; 4.55 (s, 2H); 7.30 (m, 5H) . EXAMPLE 28 (S)-2-Decanesulfonylaminooctanol-l-phospho-2-benzy- loxyethanol (I, R 1 -H, n-6, A-S0 2 , R 2 -(CH 2 ) 9 CH 3 , B=0, R 3 -CH 2 CH 2 OCH 2 C 6 H 5 ). Following the process described in Example 26, starting from (S)-2-decanesulfonylaminooctanol, the ti- tie compound is prepared as a yellowish oil (60 % yield) . [tf] D 20 =-6.8° (c=0.43, chloroform). N.M.R. 1 H (300 MHz, CDC1 3 ) £ ppro: 0.87 (t, 6H) ; 1.25 (m, 24H); 1.78 (m, 2H) ; 2.99 (t, 2H) ; 3.48 (m, 1H); 3.67 (m, 2H); 3.90 (m, 1H) ; 4.10 (m, 1H) ; 4.18 (m, 2H) ; 4.55 (s, 2H); 7.30 (m, 5H) . EXAMPLE 29 (R)-2-Decanesulfonylaminohexanol-l-phospho-2-benzy- loxyethanol (I, R^H, n-4, A-S0 2 , R 2 -(CH 2 ) g CH 3 , B=0, R 3 -CH 2 CH 2 OCH 2 C 6 H 5 ). Following the process described in Example 26, starting from (R)-2-decanesulfonylaminohexanol, the ti¬ tle compound is prepared as a yellowish oil (52 % yield) . [^] D 20 =+10.1 β (c-0.68, chloroform). N.M.R. 1 H (300 MHz, CDC1 3 ) S ppm: 0.87 (t, 6H) ; 1.29 (m, 20H); 1.78 (m, 2H) ; 2.99 (t, 2H) ; 3.48 (m, 1H) ; 3.68 (m, 2H); 3.90 (m, 1H) ; 4.12 (m, 1H); 4.19 (m, 2H) ; 4.56 (s, 2H); 7.33 (m, 5H) . EXAMPLE 30 (S)-2-Decanesulfonylaminohexanol-l-phospho-2-benzyloxy¬ ethanol (I, R X -H, n-4, A-S0 2 , R 2 -(CH 2 ) g CH 3 , B=0, R 3 -CH 2 CH 2 OCH 2 C 6 H 5 ) . Following the process described in Example 26, starting from (S)-2-decanesulfonylaminohexanol, the ti¬ tle compound is prepared as a colourless oil (55 % yield) . [*(] D 20 =-9.3 β (c=0.7, chloroform). N.M.R. 1 H (300 MHz, CDC1 3 ) S ppm: 0.87 (t, 6H) ; 1.29 (m, 20H); 1.78 (m, 2H) ; 2.99 (t, -2H) ; 3.48 (m, 1H) ; 3.68 (m, 2H); 3.90 (m, 1H) ; 4.12 (m, 1H) ; 4.19 (m, 2H) ; 4.56 (s, 2H); 7.33 (m, 5H). EXAMPLE 31 2-Decanesulfonylaminooctanol-1-phosphoglycol (I, R -H, n-6, A-S0 2 , R 2 -(CH 2 ) g CH 3 , B=0, R 3 -CH 2 CH 2 OH) . A solution of 2-decanesulfonylaminooctanol-1-pho- spho-2-benzyloxyethanol (0.29 g, 0.51 mmol) in methanol (20 ml) is added with 0.029 g of 20 % Pd(OH) 2 _c and the mixture is stirred at room temperature for 18 h, under hydrogen atmosphere. The mixture is filtered and evapo- rated to dryness to obtain 0.16 g of the title compound as a colourless oil (68 % yield). N.M.R. X H (300 MHz, CT> 3 OD) S ppm: 0.99 (t, 6H) ; 1.37 (m, 24H); 1.80 (m, 2H) ; 3.10 (m, 2H) ; 3.50 (m, 1H); 3.72 (m, 2H) ; 3.85 (m, 2H) ; 3.96 (m, 2H) . EXAMPLE 32 2-Dodecanoylaminooctanol-l-phospho-2-benzyloxyethanol (I, R 1 -H, n-6, A-CO, R 2 -(CH 2 ) 1() CH 3 , B=0, R 3 -CH 2 CH 2 OCH 2 C 6 H 5 ) . Following the process described in Example 26, starting from 2-dodecanoylaminooctanol, the title com¬ pound is prepared as a yellowish oil (78 % yield) . N.M.R. 1 H (300 MHz, CDC1 3 ) & ppm: 0.87 (t, 6H) ; 1.25 (m, 24H); 1.60 (m, 4H); 2.20 (t, 2H) ; 3.67 (m, 2H) ; 4.05 (m, 5H) ; 4.55 (s, 2H) ; 7.33 (m, 5H) . EXAMPLE 33 2- ( 3-Phenylpropanesu lfonylamino) octanol-l-phospho-2- benzyloxyethanol (I, R^H, n-6, A=S0 2 , R 2 -(CH 2 ) 3 C g H 5 , B-O, R 3 -CH 2 CH 2 OCH 2 C 6 H 5 ). Following the process described in Example 26, starting from 2-(3-phenylpropanesulfonylamino)octanol, the title compound is prepared as a colourless oil (52 % yield). N.M.R. 1 H (300 MHz, CDC1 3 ) £ ppro : 0.88 (t, 3H) ; 1.25 (m, 10H); 2.05 (m, 2H) ; 2.65 (t, 2H); 2.98 (m, 2H) ; 3.38 (m, 1H); 3.55 (m, 2H) ; 3.70-3.90 (m, 2H) ; 4.00 (m, 2H); 4.50 (s, 2H) ; 7.20 (m, 10H) . EXAMPLE 34 2-Decanesulfonylamino-4-phenylbutanol-l-phospho-2-ben¬ zyloxyethanol (I, R 1 -C 6 H 5 , n=2, A=S0 2 , R 2 -(CH 2 ) g CH 3 , B-O, R 3 -CH 2 CH 2 OCH 2 C 6 H 5 ) . Following the process described in Example 26, starting from 2-decanesulfonylamino-4-phenylbutanol, the title compound is prepared as a colourless oil (57 % yield). N.M.R. X H (300 MHz, CDC1 3 ) £ Ppm: 0.88 (t, 3H) ; 1.25 (m, 14H); 1.78 (m, 4H) ; 2.65 (m, 2H) ; 2.98 (m, 2H) ; 3.50 (m, 1H); 3.60 (m, 2H) ; 3.98 (m, 1H); 4.15 (m, 3H) ; 4.50 (m, 2H); 7.25 (m, 10H). EXAMPLE 35 2-Dodecanoylaminooctanol-l-phosphoserine (I, R^-H, n-6, A-CO, R 2 -(CH 2 ) 1() CH 3 , B=0, R 3 -CH 2 CH(COOH)NH 2 ) . Following the process described in Example 26, starting from 2-dodecanoylaminooctanol and (N-benzy- loxycarbonyDserine benzyl ester, 2-dodecanoylaminooc- tanol-l-phospho(N-benzyloxycarbonyl)-serine benzyl ester is obtained, which is subjected to catalytic hy- drogenation following the process described in Example 31, to obtain the title compound as a white solid mel¬ ting at 129-131°C (50 % total yield). N.M.R. 1 H (300 MHz, CD 3 OD) h ppm: 0.98 (t, 6H) ; 1.38 (m, 24H); 1.69 (m, 4H) ; 2.31 (t, 2H) ; 3.89 (m, 2H) ; 4.10 (m, 1H); 4.37 (m, 3H). EXAMPLE 36 2-Decanesulfonylaminooctanol-l-phosphoethanolamine (trifluoroacetic acid salt) (I, R -H, n-6, A-SO 2' R 2 -(CH 2 ) g CH 3 , B-O, R 3 -CH 2 CH 2 NH 2 ). Following the process described in Example 26, starting from 2-decanesulfonylaminooctanol and N-(tert- butoxycarbonyl)ethanolamine, 2-decanesulfonylaminoocta- nol-l-phospho(N-tert-butoxycarbonyl)ethanolamine is prepared, which is subjected to acid hydrolysis with trifluoroacetic acid in methylene chloride. After 4 h stirring at room temperature and evaporation of the vo- latiles, the title compound is obtained a semisolid oil (62 % yield). N.M.R. 1 H (300 MHz, CD 3 OD) £ ppm: 0.89 (t, 6H) ; 1.32 (m, 24H); 1.79 (m, 2H) ; 3.07 (t, 2H) ; 3.19 (m, 2H); 3.47 (m, 1H); 3.89 (m, 2H) ; 4.12 (m, 2H) . EXAMPLE 37 2-Dodecanoylaminooctanol-l-phosphoethanolamine (acetic acid salt) (I, R 1 -H, n=6, A-CO, R 2 -(CH 2 ) CH 3 , B=0, R 3 -CH 2 CH 2 NH 2 ). Following the process described in Example 26, starting from 2-dodecanoylaminooctanol and N- (benzyloxycarbonyl)ethanolamine, 2-dodecanoyl-amino- octanol-l-phospho(N-benzyloxycarbonyl)ethanolamine is prepared, which is subjected to catalytic hydrogenation with 10% Pd-C in 1:1 acetic acid:methanol, according to the procedure described in Example 31, to obtain the title compound as a white solid melting at 149-152°C (62 % yield). N.M.R. 1 H (300 MHz, CD 3 OD) ζ " ppm: 0.87 (t, 6H) ; 1.28 (m, 24H); 1.60 (m, 4H) ; 2.15 (s, 3H) ; 2.20 (m, 2H) ; 3.16 (m, 2H); 3.80 (m, 2H); 4.03 (m, 3H). EXAMPLE 38 2-Decanesulfonylaminooctanol-l-phosphoethanol (I, R -H, n-6, A-S0 2 , R 2 -(CH 2 ) g CH 3 , B=0, R 3 =CH 2 CH 3 ). Following the process described in Example 26, starting from 2-decanesulfonylaminooctanol and ethanol, the title compound is prepared as a colourless oil (68 % yield). N.M.R. 1 H (300 MHz, CDC1 3 ) ppm: 0.88 (t, 6H) ; 1.28 (m, 25H); 1.55 (m, 2H) ; 1.80 (m, 2H) ; 3.00 (t, 2H) ; 3.50 (m, 1H); 3.90-4.20 (m, 4H) . EXAMPLE 39 2-Dodecanoylaminooctanol-l-phosphoethanol (I, R -H, n-6, A-CO, R 2 -(CH 2 ) 10 CH 3 , B=0, R 3 -CH 2 CH 3 ). Following the process described in Example 26, starting from 2-dodecanoylaminooctanol and ethanol, the title compound is prepared as a colourless oil (60 % yield) . N.M.R. 1 H (300 MHz, CD 3 OD) £ ppm: 0.98 (t, 6H) ; 1.34 (m, 27H); 1.69 (m, 4H) ; 2.29 (t, 2H) ; 3.80-4.15 (m, 5H). EXAMPLE 40 2-Dodecanoylaminooctanol-l-phosphate (I, R -H, n-6, A-CO, R 2 -(CH 2 ) 10 CH 3 , B=0, R 3 -H) . Following the process described in Example 26, but carrying out directly the oxidation of the intermediate phosphonate with iodine, water and pyridine as descri¬ bed in said example, starting from 2-dodecanoylaminooc- tanol, the title compound is prepared as a colourless oil (60 % yield). N.M.R. 1 H (300 MHz, CD 3 OD) £ ppm: 0.98 (t, 6H) ; 1.38 (m, 24H); 1.69 (m, 4H) ; 2.29 (t, 2H) ; 3.86 (t, 2H) ; 4.05 (m, 1H). EXAMPLE 41 2-Decanesulfonaminooctyl butylphosphonate (I, R -H, n-6, A-S0 2 , R 2 -(CH 2 ) g CH 3 , B-CH 2 , R 3 =(CH 2 ) 2 CH 3 ) . Methyl butylphosphonic acid chloride A 80% NaH suspension (1.26 g, 42.0 mmol) and dry DMF (80 ml) is added at 0 β C with 3.4 ml (36.5 mmol) of dimethylphosphite. The mixture is stirred for 1 h at room temperature, then it is left to cool to 0 β C and added with a solution of n-butyl bromide (3.9 ml, 36.5 mmol) in DMF (10 ml). The mixture is stirred for 4 h at room temperature, then added with some drops of metha¬ nol and water, extracted with ethyl ether, dried and the solvent is evaporated off, to obtain 4.2 g of di¬ methyl butylphosphonate as a colourless oil. The obtai¬ ned compound is dissolved in 60 ml of a 1.7 M NaOH methanol solution. The mixture is stirred at 100°C for 7 h, after that is evaporated to dryness, redissolved in water and extracted with ethyl ether. The ether phase is washed with diluted HCl to acid pH, dried and the solvent is removed, to obtain 3.3 g methyl butyl¬ phosphonic acid (85% yield). This compound is added with 50 ml of thionyl chloride and the mixture is stir- red at 80 β C for lh, then it is evaporated to dryness to obtain a crude compound formed mainly by the title com- pound (quantitative yield). N.M.R. 1 H (300 MHz, CDC1 3 ) ξ p pm: 0.90 (t, 3H) ; 1.40 (m, 2H); 1.65 (m, 2H) ; 2.10 ( , 2H) ' ; 3.82 (d, 3H). 2-Decanesulfonaminooctyl butylphosphonate A solution of 2-decanesulfonylaminooctanol (0.45 g, 1.3 mmol) in chloroform (23 ml) is added with triethylamine (0.9 ml, 6.4 mmol), DMAP (0.16 g, 0.28 mmol) and methyl butylphosphonic acid chloride (0.36 g, 2.6 mmol). The mixture is stirred at 0°C for 18 h, di- luted with chloroform, washed with 0.2 M HCl, dried and the solvent is removed, to obtain a crude compound mainly formed by 2-decanesulfonamidooctyl methyl butyl¬ phosphonate. This crude compound is redissolved in 5 ml of dry chloroform and 4 ml of trimethylamine are added thereto. The mixture is stirred in a sealed reactor at 65-70 β C for 24 h. After that it is evaporated to dry¬ ness, to obtain a residue which is purified by chroma¬ tography on a silica gel column. Eluting with 20:1 chloroform:methanol, 0.33 g of the title compound are obtained as a colourless oil (57 % yield). N.M.R. 1 H (300 MHz, CDC1 3 ) £ ppm: 0.88 (m, 9H); 1.30 (m, 24H); 1.50 (m, 4H); 1.75 (m, 4H) ; 3.00 (t, 2H) ; 3.48 (m, 1H); 4.01 (m, 2H) . EXAMPLE 42 2-Decanesulfonaminooctyl (4-phenylbutyl)phosphonate (I, R 1 -H, n-6, A-S0 2 , R 2 -(CH 2 ) g CH 3 , B=CH 2 , R 3 -(CH 2 ) 3 CgH 5 ) . Following the process described in Example 41, starting from 2-decanesulfonylaminooctanol and methyl (4-phenylbutyl)phosphonic acid chloride, the title com- pound is prepared as a colourless oil (86 % yield). N.M.R. 1 H (300 MHz, CDC1 3 ) S ppm: 0.87 (m, 6H) ; 1.20- 1.75 (m, 32H) ; 2 .59 ( t , 2H) ; 3 .02 (m , 2H ) ; 3 .48 (m, 1H ) ; 3 . 80 ( m, 1H ) ; 4 . 05 ( m, 1H ) ; 7 . 20 ( m, 5H ) . EXAMPLE 43 2-Dodecanoylaminooctyl butylphosphonate (I, R =H, n=6, A=CO, R 2 =(CH 2 ) 1() CH 3 , B=CH 2 , R 3 =(CH 2 ) 2 CH 3 ) . Following the process described in Example 41, starting from 2-dodecanoylaminooctanol, the title com¬ pound is prepared as a colourless oil (53 % yield). N.M.R. X H (300 MHz, CDC1 3 ) S ppm: 0.88 (m, 9H) ; 1.20- 1.80 (m, 34H); 2.22 (t, 2H) ; 3.65 (m, 1H) ; 3.81 (m, 1H) ; 4.00 (m, 1H) . Determination of the inhibition of phospholipase A2. The activity of A 2 is determined by quantifica¬ tion of the radioactively labelled fatty acid ( 14C-arachidonic) which esterifies the sn-2 position of the phospholipid substrate and which is released by the action of the enzyme. As a substrate l-palmitoyl-2- 14 [1- C]arachidonoylphosphatidylethanola-mine vesicles are used, prepared according to the following process: the desired amount of phospholipid is resuspended in 50 mM HEPES buffer, pH 7.0, by strong stirring, the su¬ spension is heated to 60 β C and subsequently sonicated in a bath until the mixture becomes translucent. The sonicated vesicles are kept at room temperature for 30 minutes. PL 2 from previously purified human synovial liquid is used as an enzyme. The reaction mixture contains the necessary amount of vesicles corresponding to.200 nmoles of phospholipid and 10,000 d.p.m., CaCl 2 (2mM) and NaCl (150mM) , in a total volume of 0.5 ml. The reaction is started by ad¬ dition of the enzyme (50-100 ng). After 4 minutes at 37°C the reaction is interrupted adding 3.0 ml of a CHC1 3 :CH 3 0H mixture (1:2 v/v). The lipids are extracted according to the procedure by Bligh & Dyer and the re¬ action products are separated by thin layer chromato- graphy and quantified by liquid scintillation. The evaluation of the inhibiting effect on the PLA 2 activity by the compounds of the present invention is carried out by formation of mixed vesicles, which are used subsequently as a substrate for the enzyme. The preparation of said mixed vesicles includes a first step in which known amounts of substrate and compound are mixed in a suitable solvent. The total amount of lipid is kept constant (200 nmoles) varying the molar fraction of the compound (X^ . The solvent of the mix- ture is evaporated off under nitrogen stream, and the mixed vesicles are formed as described above. In both cases (absence and presence of the inhibi¬ tor) the enzymatic activity is defined as nmoles of [ 14 C]-arachidonic acid released per minute. The inhibiting capability of the different com¬ pounds is expressed as the molar fraction of the pro¬ duct in the vesicle (X i ) which causes a 50% decrease of the enzyme activity with respect to the control in the absence of inhibitor. Some examples of the obtained re- suits are reported in table 1. For comparison, 2-dodecanoylaminooctanol-l-phospho-2-benzyloxyethanol (compound A) was also tested, which was described in literature as a strong inhibitor of PL 2 iii vitro (De Haas G. H. et al., Biochim. Biophys. Acta, 1046, 249 (1990)). Table 1. Inhibiting effect on PLA2 from human synovial liquid. Compound N* Xi(50) 26 0.0036 27 0.0048 28 0.015 31 0.026 32 0.024 35 0.050 39 0.0025 40 0.040 41 0.050 43 0.012 Compound A 0.010 Antiinflammatory activity. Inhibition of the carraqee- nin plantar oedema in the rat. The antiinflammatory action of the compounds of the present invention is determined by a standard test based on the procedure by Winter C.A. et al. (Proc. Soc. Exp. Biol. Med., Ill, 544 (1962)) . In this test, male Sprague-Dawley rats of 90-110 g are used, which are randomized in groups of 5 animals. The compound un¬ der test is administered intravenously in the tail la¬ teral vein. The compound is suspended in Tween 20 (2-3% final concentration) and physiological serum is added to obtain a solution of the desired concentration of the compound, the administered volume being 2.5 ml/kg. Immediately after the injection of the compound, a sub- plantar injection of 0.1 ml of 1% carrageenin in phy- siological serum is performed in the right paw of the rat. In each test, a control group is systematically used, which is administered with the vehicle only. The paw inflammation is evaluated by measuring its volume with a water plethysmograph 1, 3 and 6 hours after in¬ ducing the inflammation. The determination of the inhi- bition percentage of the inflammation is calculated by the following formula: % Inhibition = (1 - A/B) x 100 wherein A is the average of the swelling volume in the group of treated animals and B is the average of the swelling volume in the control group. Table 2 shows the inhibition values found for some of the compounds of the present invention. For compari¬ son purposes, the inhibition values of indomethacin and ketoprofen are also included as reference. The inhibi- tion value found for Compound A, a structural analogous of the compounds described in the present patent, is also shown. Table 2. Antiinflammatory effect, Carrageenin plantar oedema test in the rat. Compound N- Dose % Inhibition (mg/Kg) (3 hours) 26 10 41 37 26 36 19 27 12 33 35 18 18 23 17 22 22 37 37 14

Claims: CLAIMS 1. Compounds of formula ( I ) I wherein R is hydrogen or phenyl; n is an integer from 2 to 18 included; A is a -CO- or -S0 2 - group; R 2 is a C.-C 20 straight or branched alkyl group or a phenylalkyl of less than 20 carbon atoms; B is an oxygen atom or a methylene group; 3 R is hydrogen, a C,-C 8 straight or branched alkyl, a phenylalkyl group of less than 12 carbon atoms, a 4 -(CH 2 ) OR group, wherein m is a integer from 2 to 6 4 and R is hydrogen, a C,-C 4 straight or branched alkyl group, or a phenylalkyl group of less than 10 carbon atoms, or a -(CH 9 ) CH(R )NHR group, wherein p is a in- teger from 1 to 4 P , R5 is hydrogen or a carboxyl group and R is hydrogen, a C,-C. straight or branched alkyl group, a phenylalkyl group of less than 10 carbon atoms; with the proviso that the -B-R group cannot be -OCH 2 CH 2 OH when A is -CO- and R is H, nor when A is -S0 2 ~, R is hydrogen and n is lower than 5; the stereoisomers and mixtures thereof, as well as the pharmaceutically acceptable salts thereof. 2. Compounds as claimed in claim 1, wherein B is oxy- 3 gen and R is hydrogen, a C,-C 8 straight alkyl group, a phenylalkyl group of less than 12 carbon atoms, a 4 -(CH,,) OR group, wherein m is an integer from 2 and 4 4 and R is hydrogen or a phenylmethyl group, or a -(CH 2 ) CH(R )NHR group, wherein p is an integer from 1 and 4, R is hydrogen or a carboxy group and R is hy- drogen or a phenylmethyl group, 3 3 3.. CCoommppoouunnddss aaccccoorrddiinng to claim 2, wherein R is hy- drogen, ethyl or butyl. 4. Compounds according to claim 2, wherein R is the -(CH 2 ) 2 OR 4 group, wherein R4 is hydrogen or phenyl- methyl. 5. Compounds according to claim 2, wherein R 3 is the -CH 2 CH(R 5)NHR6 group, wherein R5 is hydrogen or a car¬ boxy group and R is hydrogen. 6. Compounds according to claim 1, wherein B is a methylene group and R is a C,-C 8 straight alkyl group or a phenylalkyl group of less than 12 carbon atoms. 7. Compounds according to claim 2, wherein A is a 2 -S0 2 - group and R is a .-C 2Q straight alkyl group or a phenylalkyl group of less than 20 carbon atoms. 8. Compounds according to claim 6, wherein A is a -S0 2 - group and R is a C.-C 2Q straight alkyl group or a phenylalkyl group of less than 20 carbon atoms. 9. Compounds according to claim 2, wherein A is a 2 -CO- group and R is a C-,-C 20 straight alkyl group or a phenylalkyl group of less than 20 carbon atoms. 10. Compounds according to claim 6, wherein A is a 2 -CO- group and R is a c -,-C 20 straight alkyl group or a phenylalkyl group of less than 20 carbon atoms. 11. Compounds according to the above claims, which are: 2-Decanesulfonylaminooctanol-l-phospho-2-benzyloxyetha- nol , (R)-2-Decanesulfonylaminooctanol-l-phospho-2-benzy- loxyethanol, (S)-2-Decanesulfonylaminooctanol-l-phospho-2-benzy- loxyethanol, (R)-2-Decanesulfonylaminohexanol-l-phospho-2-benzy- loxyethanol, (S)-2-Decanesulfonylaminohexanol-l-phospho-2-benzy- loxyethanol, 2-Decanesulfonylaminooctanol-l-phosphoglycol, 2-Dodecanoylaminooctanol-l-phospho-2-benzyloxyethanol, 2-(3-Phenylpropanesulfonylamino)octanol-l-phospho-2- benzyloxyethanol, 2-Decanesulfonylamino-4-phenylbutanol-l-phospho-2-ben- * zyloxyethanol, 2-Dodecanoylaminooctanol-l-phosphoserine, 2-Decanesulfonylaminooctanol-1-phosphoethanolamine (salt of the acid trifluoroacetic) , 2-Dodecanoylaminooctanol-l-phosphoethanolamine (salt of the acetic acid) , 2-Decanesulfonylaminooctanol-l-phosphoethanol, 2-Dodecanoylaminooctanol-l-phosphoethanol, 2-Dodecanoylaminooctanol-l-phosphate, 2-Decanesulfonaminooctyl butylphosphonate, 2-Decanesulfonaminooctyl (4-phenylbutyl)phosphonate, 2-Dodecanoylaminooctyl butylphosphonate. 12. A process for the preparation of the compounds of general formula (I) , in which process a compound of formula (II) of suitable stereochemistry at the 2-car- bon, (CH,),, R 1 R 2— A —NH—CH CH 2 —OH XI wherein R 1, n, A and R2 have the above mentioned mea¬ nings, is subjected to one of the following reactions: a) When in (I) B is a oxygen, compound (II) is reacted with a reactive PX 3 , wherein X is a halogen, in the presence of a proton-binding base and a mildly nucle- ophilic base, in suitable organic solvents, at a tempe¬ rature from 0 β and 40 β C for a time from 3 and 18 hours, thereby obtaining a compound of formula (III), III subsequently this intermediate is reacted with a com- pound (IV), HO-R 7 (IV) wherein, R 7 can be equivalent to the group R3 in for- 3 mula (I) except for hydrogen; when in (I) R is a -(CH 2 ) OH group, the hydroxy group being suitably pro- tected; when in (I) R 3 is a -(CH 2 ) ι NH 2 group, the amino group being suitably protected, ; and when in (I) 3 R is a -(CH 2 ) (COOH)NH 2 group, the carboxy and amino groups being suitably protected, in an organic solvent, at a temperature from 0 β to 25°C for a time from 1 to 6 hours, to obtain an intermediate of formula (V), V which is oxidized in a suitable solvent at a tempera¬ ture from 0° to 25 β C for a time from 1 to 5 hours, to obtain an intermediate (V ), VI wherein R 1, n, A, R2 and R7 have the above mentioned meanings; finally, if necessary, converting compound (VI) into (I) by removing any protecting groups present in R 7 ; 3 b) When in (I) B is oxygen and R is hydrogen, the compound (II) is reacted as in a) to give the intermediate (III) which is then directly oxidized; c) When in (I) B is a methylene group, compound (II) is reacted with a reactive (V I), VII wherein Y and Z are halogen or a methoxy group, in the presence of an amine, in a suitable organic solvent, at a temperature from 0° to 40°C for a time from 3 to 24 hours, to obtain an intermediate of formula (VIII), VI I I 1 2 7 wherein R , n , A , R , Z and R have the above mentioned meanings ; compound (VTII ) is subjected to acid hydroly¬ sis in aqueous medium, when Z is halogen , or to treat¬ ment with a suitable nucleophilic agent , when Z is a methoxide group , to obtain a compound (IX) , I X wherein R 1, n, A, R2 and R7 have the above mentioned meanings; finally, if necessary, compound (IX) is con¬ verted into (I) by removing any protecting groups pre- 13. Pharmaceutical compositions containing one com¬ pound of claims 1 to 11 as the active ingredient, to¬ gether with suitable excipients. 14. The use of the compounds of claims 1 to 11 for the preparation of a medicament for the treatment of in- flammatory and allergic diseases such as rheumatic arthritis, tendinitis, bursitis, psoriasis, bronchial asthma.

Inventors: CARGANICO GERMANO, GARCIA PEREZ M LUISA, MAULEON CASELLAS DAVID, CARGANICO, GERMANO, GARCIA PEREZ, M. LUISA, MAULEON CASELLAS, DAVID
Applicants: CARGANICO GERMANO, GARCIA PEREZ M LUISA, MAULEON CASELLAS DAVID, MENARINI LAB, CARGANICO, GERMANO, GARCIA PEREZ, M. LUISA, LABORATORIOS MENARINI S.A., MAULEON CASELLAS, DAVID
Application year: 1994
Main classification: C07F9
IPC codes: C07F9